<DOC>
	<DOCNO>NCT02102776</DOCNO>
	<brief_summary>The purpose randomized multi-center clinical trial compare efficacy safety intraoperative mitomycin C ( MMC ) , amniotic membrane transplantation ( AMT ) Conjunctival Autograft ( CAG ) primary pterygium surgery . The investigator also evaluate particular risk factor related pterygium recurrence .</brief_summary>
	<brief_title>Intraoperative Mitomycin C , Amniotic Membrane Transplantation Conjunctival Autograft Primary Pterygium</brief_title>
	<detailed_description>Patients primary pterygium randomly assign undertake pterygium excision follow intraoperative mitomycin C application , amniotic membrane transplantation conjunctival autograft five clinical center . Multi-center collaboration quality monitoring base website design study . The patient follow least 12 month . Corneal Recurrence primary outcome measure , consider fibrovascular ingrowth beyond limbus conjunctival drag .</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Primary pterygium Willingness participate research project attend research followup Adults ( age 18 80 year old ) Patients must meet follow exclusion criterion Pregnant , breastfeed woman patient poor general health Patients significant ocular lid pathology , Sjogren 's Syndrome , infection , exposure keratitis , glaucoma , active uveitis , retinal detachment trauma Patients previous surgery ocular surface , trabeculectomy , strabismus surgery Patients allergy intraoperative postoperative drug , mitomycin C , tobramycin local anesthetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Primary Pterygium</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Amniotic membrane transplantation</keyword>
	<keyword>Conjunctival autograft</keyword>
	<keyword>Multi-center randomize clinical trial</keyword>
</DOC>